


Assessment of benefits and risks of an additional 18-month treatment with warfarin versus placebo in patients with a first unprovoked proximal deep-vein thrombosis initially treated for 6 months

Multicenter, randomized, double-blind, controlled trial

104 patients with an unprovoked proximal deep-vein thrombosis initially treated for 6 months



After a first unprovoked proximal deep-vein thrombosis treated during 6 months, an additional 18 months of warfarin therapy reduced the composite of recurrent venous thrombosis and major bleeding compared to placebo